Kristy Solis
Family · Henderson, NVNPI 1215584552
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,034 of the $23,226 with a category attached, or 86.3%. It is spread thinly across 57 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $6,362 and has fallen 54.0% since, to $2,930 in 2025. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,069 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Novartis$2K
- AstraZeneca$2K
- Amgen$2K
- Lilly USA, LLC$1K
- Biohaven Pharmaceuticals, Inc.$1K
- plus $13K from 51 others
What the payments were for
- Consulting fees$8003%
- Speaking & faculty fees$1201%
- Travel & lodging$1,3856%
- Food & beverage$20,03486%
- Education$8284%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,733
- NURTEC ODT$1,051
- Repatha$785
- AFREZZA$233
- ISTURISA$130
- FARXIGA$120
- VYVGART HYTRULO$120
- MOUNJARO$120
- CRYSVITA$120
- Wegovy$119
- RYBELSUS$118
- DEXCOM G6 TRANSMITTER$112
How this compares
$23,226 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 258 | $400,156 |
| OzempicSemaglutide | 226 | $393,323 |
| JardianceEmpagliflozin | 137 | $155,977 |
| TrulicityDulaglutide | 52 | $95,290 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 64 | $85,587 |
| FarxigaDapagliflozin Propanediol | 81 | $82,778 |
| RybelsusSemaglutide | 50 | $69,405 |
| ProliaDenosumab | 37 | $64,086 |
| TymlosAbaloparatide | 18 | $49,950 |
| Xigduo XrDapaglifloz Propaned/Metformin | 40 | $47,214 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $45,402 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $43,452 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $42,480 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $40,855 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $32,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,258 | $502,541332 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $2,174 | $467,143287 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $701 | $270,765223 claims |
| AstraZenecaFarxiga | $2,026 | $82,77881 claims |
| AmgenProlia | $1,899 | $64,08637 claims |
| Radius Health, Inc.Tymlos | $990 | $49,95018 claims |
| MerckJanuvia | $71 | $29,54824 claims |
| BayerKerendia | $778 | $28,00630 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $500 | $26,87914 claims |
| Mannkind CorporationAfrezza | $1,025 | $19,55911 claims |
| AbbVieSynthroid | $1,096 | $3,37338 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,781286 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Henderson
- Joseph LauHenderson$18K
- Judith YuHenderson$14K
- Daniel Sam AciertoHenderson$11K
- Reiko TapiaHenderson$10K
- Francis TorresHenderson$8K
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Erin WilkinsonLas Vegas$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.